{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:38:37Z","timestamp":1793234317257,"version":"4.5.0"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"3","funder":[{"DOI":"10.13039\/100012068","name":"Central Texas Veterans Health Care System","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012068","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Ibrutinib has been a first-line treatment for chronic lymphocytic leukemia since 2014. Case reports of hepatitis B virus (HBV) reactivation after ibrutinib initiation have been presented. The association between the risk of HBV reactivation and ibrutinib initiation remains unclear. This nationwide study aimed to estimate the incidence of HBV reactivation after ibrutinib initiation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Method<\/jats:title>\n                  <jats:p>This study included patients who received ibrutinib between 1 February 2014 and 31 October 2019. Possible reactivations were searched by (1) changes in HBV surface antigen or HBV DNA from no data or negative status to positive after ibrutinib initiation, (2) alanine aminotransferase levels that were at least 3 times the baseline value after ibrutinib initiation, and (3) new antiviral prescriptions against HBV after ibrutinib initiation. Individual chart reviews were conducted to identify HBV reactivation attributed to ibrutinib. The cumulative incidence of HBV reactivation was calculated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total 4130 patients were eligible during the study period. Of these, patients with negative HBV core antibody (anti-HBcAb; n = 1670) and patients who were taking antivirals against HBV (n = 60) were excluded. There were 2219 patients without anti-HBcAb testing results. Among the remaining 181 patients with positive anti-HBcAb, 7 HBV reactivations were directly attributable to ibrutinib treatment after chart review, for a 3.9% cumulative incidence.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our study revealed a low cumulative incidence of HBV reactivation after ibrutinib initiation among patients with previous anti-HBcAb positivity, indicating a moderate risk of HBV reactivation.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofae008","type":"journal-article","created":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T21:10:20Z","timestamp":1704921020000},"source":"Crossref","is-referenced-by-count":1,"title":["Risk of Hepatitis B Reactivation in Patients Receiving Ibrutinib: The National Veterans Affairs Cohort"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6272-0867","authenticated-orcid":false,"given":"Ting-Yi","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Medicine, Central Texas Veterans Health Care System , Temple, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A","family":"Jacob","sequence":"additional","affiliation":[{"name":"Veterans Affairs Heart of Texas Health Care Network , VISN 17 PBM, Arlington, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D","family":"Coppin","sequence":"additional","affiliation":[{"name":"Department of Research, Central Texas Veterans Health Care System , Temple, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3916-952X","authenticated-orcid":false,"given":"Chetan","family":"Jinadatha","sequence":"additional","affiliation":[{"name":"Department of Medicine, Central Texas Veterans Health Care System , Temple, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,1,10]]},"reference":[{"key":"2024032722034314300_ofae008-B1","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(13)70513-8","article-title":"Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b\/2 trial","volume":"15","author":"O\u2019Brien","year":"2014","journal-title":"Lancet Oncol"},{"key":"2024032722034314300_ofae008-B2","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1182\/blood-2018-01-826495","article-title":"Risk of hepatitis B virus reactivation in patients treated with ibrutinib","volume":"131","author":"Hammond","year":"2018","journal-title":"Blood"},{"key":"2024032722034314300_ofae008-B3","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.3324\/haematol.2021.280325","article-title":"Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis: a retrospective multicentric GIMEMA study","volume":"107","author":"Innocenti","year":"2022","journal-title":"Haematologica"},{"key":"2024032722034314300_ofae008-B4","doi-asserted-by":"crossref","first-page":"982346","DOI":"10.3389\/fimmu.2022.982346","article-title":"Risk of HBV reactivation in relapsed or refractory diffuse large B-cell lymphoma patients receiving Bruton tyrosine kinase inhibitors therapy","volume":"13","author":"Ni","year":"2022","journal-title":"Front Immunol"},{"key":"2024032722034314300_ofae008-B5","first-page":"424","article-title":"Occult HBV reactivation induced by ibrutinib treatment: a case report","volume":"78","author":"de J\u00e9sus Ngoma","year":"2015","journal-title":"Acta Gastroenterol Belg"},{"key":"2024032722034314300_ofae008-B6","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1016\/j.clml.2019.12.006","article-title":"Hepatitis B virus-associated liver failure in a patient with B-cell non-Hodgkin lymphoma after anti-cancer therapy including ibrutinib","volume":"20","author":"Malek","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2024032722034314300_ofae008-B7","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00277-016-2917-2","article-title":"Severe hepatitis B virus reactivation related to ibrutinib monotherapy","volume":"96","author":"Herishanu","year":"2017","journal-title":"Ann Hematol"},{"key":"2024032722034314300_ofae008-B8","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1080\/10428194.2017.1317094","article-title":"Is HBV prophylaxis required during CLL treatment with ibrutinib?","volume":"58","author":"Tedeschi","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"2024032722034314300_ofae008-B9","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"2024032722034314300_ofae008-B10","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.gastro.2014.10.039","article-title":"American Gastroenterological association institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Reddy","year":"2015","journal-title":"Gastroenterology"},{"key":"2024032722034314300_ofae008-B11","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s10552-007-9097-2","article-title":"Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997\u20132002","volume":"19","author":"Yamamoto","year":"2008","journal-title":"Cancer Causes Control"},{"key":"2024032722034314300_ofae008-B12","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.cgh.2019.07.056","article-title":"Prevalence of hepatitis B virus exposure in the Veterans Health Administration and association with military-related risk factors","volume":"18","author":"Beste","year":"2020","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofae008\/55378645\/ofae008.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/3\/ofae008\/57090075\/ofae008.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/3\/ofae008\/57090075\/ofae008.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T22:03:56Z","timestamp":1711577036000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofae008\/7515036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,10]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,2,29]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofae008","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,3]]},"published":{"date-parts":[[2024,1,10]]},"article-number":"ofae008"}}